Across TCGA pan-cancer cohorts, IGLV3-25 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGLV3-25 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGLV3-25 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV3-25 expression acts as an unfavorable survival marker.
HNSC, LUAD, and DLBC are the cancer types where IGLV3-25 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.